Literature DB >> 32011901

Development and Progression of Radiologic Abnormalities in Individuals at Risk for Familial Interstitial Lung Disease.

Margaret L Salisbury1, Justin C Hewlett1, Guixiao Ding1, Cheryl R Markin1, Katrina Douglas1, Wendi Mason1, Adam Guttentag2, John A Phillips3, Joy D Cogan3, Sara Reiss1, Daphne B Mitchell1, Pingsheng Wu1,4, Lisa R Young1,3,5, Lisa H Lancaster1, James E Loyd1, Stephen M Humphries6, David A Lynch6, Jonathan A Kropski1,7,8, Timothy S Blackwell1,7,8.   

Abstract

Rationale: The preclinical natural history of progressive lung fibrosis is poorly understood.
Objectives: Our goals were to identify risk factors for interstitial lung abnormalities (ILA) on high-resolution computed tomography (HRCT) scans and to determine progression toward clinical interstitial lung disease (ILD) among subjects in a longitudinal cohort of self-reported unaffected first-degree relatives of patients with familial interstitial pneumonia.
Methods: Enrollment evaluation included a health history and exposure questionnaire and HRCT scans, which were categorized by visual assessment as no ILA, early/mild ILA, or extensive ILA. The study endpoint was met when ILA were extensive or when ILD was diagnosed clinically. Among subjects with adequate study time to complete 5-year follow-up HRCT, the proportion with ILD events (endpoint met or radiographic ILA progression) was calculated.Measurements and Main
Results: Among 336 subjects, the mean age was 53.1 (SD, 9.9) years. Those with ILA (early/mild [n = 74] or extensive [n = 3]) were older, were more likely to be ever smokers, had shorter peripheral blood mononuclear cell telomeres, and were more likely to carry the MUC5B risk allele. Self-reported occupational or environmental exposures, including aluminum smelting, lead, birds, and mold, were independently associated with ILA. Among 129 subjects with sufficient study time, 25 (19.4%) had an ILD event by 5 years after enrollment; of these, 12 met the study endpoint and another 13 had radiologic progression of ILA. ILD events were more common among those with early/mild ILA at enrollment (63.3% vs. 6.1%; P < 0.0001).Conclusions: Rare and common environmental exposures are independent risk factors for radiologic abnormalities. In 5 years, progression of ILA occurred in most individuals with early ILA detected at enrollment.

Entities:  

Keywords:  epidemiology; interstitial; lung diseases; pulmonary fibrosis; telomere

Mesh:

Substances:

Year:  2020        PMID: 32011901      PMCID: PMC7233345          DOI: 10.1164/rccm.201909-1834OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  35 in total

1.  High-Attenuation Areas on Chest Computed Tomography and Clinical Respiratory Outcomes in Community-Dwelling Adults.

Authors:  Anna J Podolanczuk; Elizabeth C Oelsner; R Graham Barr; Elana J Bernstein; Eric A Hoffman; Imaani J Easthausen; Karen Hinckley Stukovsky; Arindam RoyChoudhury; Erin D Michos; Ganesh Raghu; Steven M Kawut; David J Lederer
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

2.  MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis.

Authors:  Susan K Mathai; Stephen Humphries; Jonathan A Kropski; Timothy S Blackwell; Julia Powers; Avram D Walts; Cheryl Markin; Julia Woodward; Jonathan H Chung; Kevin K Brown; Mark P Steele; James E Loyd; Marvin I Schwarz; Tasha Fingerlin; Ivana V Yang; David A Lynch; David A Schwartz
Journal:  Thorax       Date:  2019-09-26       Impact factor: 9.139

3.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

4.  Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality.

Authors:  Rachel K Putman; Gunnar Gudmundsson; Gisli Thor Axelsson; Tomoyuki Hida; Osamu Honda; Tetsuro Araki; Masahiro Yanagawa; Mizuki Nishino; Ezra R Miller; Gudny Eiriksdottir; Elías F Gudmundsson; Noriyuki Tomiyama; Hiroshi Honda; Ivan O Rosas; George R Washko; Michael H Cho; David A Schwartz; Vilmundur Gudnason; Hiroto Hatabu; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

5.  Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis.

Authors:  Margaret L Salisbury; Barry H Gross; Aamer Chughtai; Mohamed Sayyouh; Ella A Kazerooni; Brian J Bartholmai; Meng Xia; Susan Murray; Jeffrey L Myers; Amir Lagstein; Kristine E Konopka; Elizabeth A Belloli; Jamie S Sheth; Eric S White; Colin Holtze; Fernando J Martinez; Kevin R Flaherty
Journal:  Eur Respir J       Date:  2018-08-16       Impact factor: 16.671

6.  CT scan findings of probable usual interstitial pneumonitis have a high predictive value for histologic usual interstitial pneumonitis.

Authors:  Jonathan H Chung; Ashish Chawla; Anna L Peljto; Carlyne D Cool; Steve D Groshong; Janet L Talbert; David F McKean; Kevin K Brown; Tasha E Fingerlin; Marvin I Schwarz; David A Schwartz; David A Lynch
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

7.  MUC5B promoter polymorphism and interstitial lung abnormalities.

Authors:  Gary M Hunninghake; Hiroto Hatabu; Yuka Okajima; Wei Gao; Josée Dupuis; Jeanne C Latourelle; Mizuki Nishino; Tetsuro Araki; Oscar E Zazueta; Sila Kurugol; James C Ross; Raúl San José Estépar; Elissa Murphy; Mark P Steele; James E Loyd; Marvin I Schwarz; Tasha E Fingerlin; Ivan O Rosas; George R Washko; George T O'Connor; David A Schwartz
Journal:  N Engl J Med       Date:  2013-05-21       Impact factor: 91.245

8.  Early interstitial lung disease in familial pulmonary fibrosis.

Authors:  Ivan O Rosas; Ping Ren; Nilo A Avila; Catherine K Chow; Teri J Franks; William D Travis; J Philip McCoy; Rose M May; Hai-Ping Wu; Dao M Nguyen; Mauricio Arcos-Burgos; Sandra D MacDonald; Bernadette R Gochuico
Journal:  Am J Respir Crit Care Med       Date:  2007-07-19       Impact factor: 21.405

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

Review 10.  Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment.

Authors:  Amarpreet Kaur; Susan K Mathai; David A Schwartz
Journal:  Front Med (Lausanne)       Date:  2017-09-25
View more
  19 in total

1.  Pulmonary fibrosis screening: quantifying the psychological impact.

Authors:  Chad A Newton
Journal:  Thorax       Date:  2021-02-23       Impact factor: 9.139

Review 2.  Update in Interstitial Lung Disease 2020.

Authors:  Anna J Podolanczuk; Alyson W Wong; Shigeki Saito; Joseph A Lasky; Christopher J Ryerson; Oliver Eickelberg
Journal:  Am J Respir Crit Care Med       Date:  2021-06-01       Impact factor: 21.405

3.  Preclinical Pulmonary Fibrosis Circulating Protein Biomarkers.

Authors:  Susan K Mathai; Jonathan Cardwell; Fabian Metzger; Julia Powers; Avram D Walts; Jonathan A Kropski; Oliver Eickelberg; Stefanie M Hauck; Ivana V Yang; David A Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2020-12-15       Impact factor: 21.405

4.  Molecular Signatures of Idiopathic Pulmonary Fibrosis.

Authors:  Iain R Konigsberg; Raphael Borie; Avram D Walts; Jonathan Cardwell; Mauricio Rojas; Fabian Metzger; Stefanie M Hauck; Tasha E Fingerlin; Ivana V Yang; David A Schwartz
Journal:  Am J Respir Cell Mol Biol       Date:  2021-10       Impact factor: 7.748

5.  Progress and Research Priorities in Imaging Genomics for Heart and Lung Disease: Summary of an NHLBI Workshop.

Authors:  Donna K Arnett; Ramachandran S Vasan; Matthew Nayor; Li Shen; Gary M Hunninghake; Peter Kochunov; R Graham Barr; David A Bluemke; Ulrich Broeckel; Peter Caravan; Susan Cheng; Paul S de Vries; Udo Hoffmann; Márton Kolossváry; Huiqing Li; James Luo; Elizabeth M McNally; George Thanassoulis
Journal:  Circ Cardiovasc Imaging       Date:  2021-08-13       Impact factor: 8.589

Review 6.  Clinical Relevance and Management of "Pre-Interstitial Lung Disease".

Authors:  Anna J Podolanczuk; Rachel K Putman
Journal:  Clin Chest Med       Date:  2021-06       Impact factor: 4.967

7.  Associations of D-Dimer with Computed Tomographic Lung Abnormalities, Serum Biomarkers of Lung Injury, and Forced Vital Capacity: MESA Lung Study.

Authors:  John S Kim; Michaela R Anderson; Elana J Bernstein; Elizabeth C Oelsner; Ganesh Raghu; Imre Noth; Michael Y Tsai; Mary Salvatore; John H M Austin; Eric A Hoffman; R Graham Barr; Anna J Podolanczuk
Journal:  Ann Am Thorac Soc       Date:  2021-11

Review 8.  Identification and Remediation of Environmental Exposures in Patients With Interstitial Lung Disease: Evidence Review and Practical Considerations.

Authors:  Carla R Copeland; Bridget F Collins; Margaret L Salisbury
Journal:  Chest       Date:  2021-02-18       Impact factor: 10.262

Review 9.  Familial Pulmonary Fibrosis: Genetic Features and Clinical Implications.

Authors:  David Zhang; Chad A Newton
Journal:  Chest       Date:  2021-06-26       Impact factor: 9.410

Review 10.  Interstitial Lung Abnormalities: State of the Art.

Authors:  Akinori Hata; Mark L Schiebler; David A Lynch; Hiroto Hatabu
Journal:  Radiology       Date:  2021-08-10       Impact factor: 29.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.